<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460589</url>
  </required_header>
  <id_info>
    <org_study_id>KNUHCRC004</org_study_id>
    <nct_id>NCT01460589</nct_id>
  </id_info>
  <brief_title>Early Commencement of Adjuvant Chemotherapy for Colon Cancer</brief_title>
  <acronym>ECTX</acronym>
  <official_title>Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study sets up the final study end point and three detailed goals as the following.&#xD;
&#xD;
      The main objective of study: This trial is done to assess the safety and benefit of early&#xD;
      adjuvant chemotherapy from 10 to 14 days after surgery compared with conventional&#xD;
      commencement after 2weeks for treatment of patients with colon cancer.&#xD;
&#xD;
      Detailed goal of study:&#xD;
&#xD;
      The primary endpoint: This study is designed to assess whether early commencement of adjuvant&#xD;
      chemotherapy improves the 3-year disease-free survival, overall survival and recurrence rate.&#xD;
&#xD;
      The secondary endpoint: This study aims to compare short-term cumulative complications&#xD;
      between early and conventional commencement of adjuvant chemotherapy after laparoscopic&#xD;
      resection of colon cancer. This study will also assess the quality of life and side effects&#xD;
      of chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment&#xD;
&#xD;
        -  day1: Oxaliplatin 85mg/m2&#xD;
&#xD;
        -  day1: Leucovorin 200mg/m2&#xD;
&#xD;
        -  day1: 5-FU 400mg/m2 IV bolus&#xD;
&#xD;
             -  2,400mg/m2 over 46 hours&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>up to 3 years after operation</time_frame>
    <description>A survival analysis will be performed using the Kaplan-Meier method, for which a comparison of the survival curve will also made using a Log-rank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>short-term cumulative surgery-related complications during chemotherapy</measure>
    <time_frame>up to 26 weeks after operation</time_frame>
    <description>A comparison of the postoperative recovery variables, the postoperative complications and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of chemotherapy</measure>
    <time_frame>during chemotherapy period</time_frame>
    <description>check Anemia, Leukopenia, Neutropenia, Thrombocytopenia, Edema, Fever, Insomnia, Asthenia, Anorexia, Nausea, Vomiting, Constipation, Diarrhea, Hand foot syndrome, Dyspepsia, Creatinine, AST, ALT, Bilirubin, abdominal pain, GI bleeding, diarrhea</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>early commencement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional commencement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals who initiate the adjuvant chemotherapy after 14 days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>timing to initiate the adjuvant chemotherapy</intervention_name>
    <description>Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours</description>
    <arm_group_label>conventional commencement</arm_group_label>
    <arm_group_label>early commencement</arm_group_label>
    <other_name>early commencement of chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligibility rule of enrollment&#xD;
&#xD;
          -  Rectal adenocarcinoma that were 15 cm or more from the anal verge&#xD;
&#xD;
          -  pathologically diagnosed stage II or III disease&#xD;
&#xD;
          -  patients who meet the discharge criteria within 10days after surgery&#xD;
&#xD;
          -  Patients with adequate hepatic, renal, and bone marrow function, and a left&#xD;
             ventricular ejection fraction of 55% or higher measured by echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An ineligibility to participate in the clinical study based on the judgment of&#xD;
             investigators from a legal perspective&#xD;
&#xD;
          -  A past history of chemotherapy&#xD;
&#xD;
          -  tumor with obstruction or perforation&#xD;
&#xD;
          -  tumor with distant metastases&#xD;
&#xD;
          -  synchronous tumor&#xD;
&#xD;
          -  relative or absolute contraindications of chemotherapy&#xD;
&#xD;
          -  Recent MI, CVA, nitrate medication&#xD;
&#xD;
          -  Severe cardiovascular disease, psychiatric disease&#xD;
&#xD;
          -  Severe hepatic dysfunction (GOT, GPT ≥100IU/L)&#xD;
&#xD;
          -  Renal dysfunction (Cr ≥2mg/dl)&#xD;
&#xD;
          -  The concurrent presence of other severe medical diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gyu seog Choi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Kyunpook National Univercity Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyu seog Choi</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Hospital</investigator_affiliation>
    <investigator_full_name>Gyu-Seog Choi</investigator_full_name>
    <investigator_title>Director, Head of colorectal cancer center, Principal Investigator, Professor</investigator_title>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

